This is a profile image of Olivier Leclerc

Olivier Leclerc

Senior PartnerSouthern California

Serves a large range of pharmaceutical, biotech, and medical-products clients, from multibillion-dollar corporations to pre-IPO start-ups, on strategic and operational improvement opportunities

Olivier assists pharmaceutical, biotechnology, and medical products clients in capturing a range of strategic and operational improvement opportunities. Specifically, he applies his expertise in global consumer products to help clients develop product-launch strategies, refine sales and marketing processes, and resolve critical pricing and reimbursement issues.

Olivier has supported various product launch efforts in therapeutic areas ranging from oncology to digestive health and medical nutrition. He collaborates with client executives to optimize commercialization and go-to-market approaches, contributing to product positioning, fulfillment, and pricing and contracting strategies. He has conducted multiple engagements on portfolio prioritization and technology assessments in biotechnology and specialty pharmaceuticals.

Olivier also has experience in helping healthcare-products companies develop and execute effective payor strategies, including strategies focused on state and federal payors and commercial payers in the United States. He is at the leading edge of our work on healthcare reform. His work typically encompasses refining pricing and contracting strategies and pull-through approaches, and conducting detailed health-economic and market-access assessments.

In addition to working directly with executives at products companies, Olivier has contributed to multiple due diligence engagements for private-equity funds that are considering investments in healthcare payers, providers, or services firms. Previously, he served Pernod Ricard and L’Oréal in Hong Kong and China in sales and marketing roles.

Olivier also leads McKinsey's digital work globally and the oncology work in the United States within our Life Sciences Practice.

Published work

Here to stay: An attractive future for medical aesthetics,” McKinsey & Company, February 2024

What early-stage investing reveals about biotech innovation,” McKinsey & Company, December 2023

What are the biotech investment themes that will shape the industry?,” McKinsey & Company, June 2022

From extreme to mainstream: The future of aesthetics injectables,” McKinsey & Company, December 2021

Moderna’s path to vaccine innovation: A talk with CEO Stéphane Bancel,” McKinsey & Company, August 2021

The promise of digital therapeutics,” McKinsey & Company, March 2020

How new biomolecular platforms and digital technologies are changing R&D,” McKinsey & Company, July 2018

Digital therapeutics: Preparing for takeoff,” McKinsey & Company, February 2018

How pharma can win in a digital world,” McKinsey & Company, December 2015

The road to digital success in pharma,” McKinsey & Company, August 2015

Five routes to more innovative problem-solving,” McKinsey Quarterly, April 2013


University of Paris
JD, French corporate and tax law

Harvard University

HEC, France
BA, business